信邦制药(002390) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥1,605,127,137.43, representing a 1.70% increase compared to ¥1,578,346,374.84 in the same period last year[2] - Net profit attributable to shareholders decreased by 27.94% to ¥52,944,770.89 from ¥73,477,230.21 year-on-year[2] - Net profit for Q1 2023 was CNY 62,648,520.70, a decrease from CNY 79,535,695.47 in Q1 2022, reflecting a decline of approximately 21.2%[16] - The total comprehensive income for Q1 2023 was ¥62,648,520.70, down from ¥79,535,695.47 in the same period last year, reflecting a decline of approximately 21%[17] - The basic and diluted earnings per share for Q1 2023 were both ¥0.03, compared to ¥0.04 in Q1 2022, indicating a 25% decrease[17] Cash Flow - The net cash flow from operating activities significantly dropped by 98.40%, amounting to ¥2,178,740.78 compared to ¥136,064,884.82 in the previous year[5] - Cash received from sales of goods and services in Q1 2023 was ¥1,465,643,505.99, a decline of about 7.4% from ¥1,582,853,471.06 in Q1 2022[20] - The net cash flow from operating activities for Q1 2023 was ¥2,178,740.78, significantly lower than ¥136,064,884.82 in Q1 2022[20] - The net cash flow from investing activities in Q1 2023 was -¥48,209,725.41, compared to -¥72,216,888.53 in Q1 2022, showing an improvement in cash outflow[21] - The net cash flow from financing activities for Q1 2023 was ¥60,850,727.62, contrasting with a negative cash flow of -¥9,290,728.22 in Q1 2022[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥9,889,925,341.80, a 0.99% increase from ¥9,793,091,573.35 at the end of the previous year[2] - Total assets as of March 31, 2023, amounted to CNY 9,889,925,341.80, compared to CNY 9,793,091,573.35 at the beginning of the year, showing an increase of about 1.0%[12] - Total liabilities as of March 31, 2023, were CNY 2,763,288,937.98, slightly up from CNY 2,728,042,922.48 at the start of the year, representing an increase of approximately 1.3%[13] Shareholder Information - The total equity attributable to shareholders increased by 0.78% to ¥6,861,396,417.39 from ¥6,808,451,646.50 at the end of the previous year[2] - The company had a total of 82,166 common shareholders at the end of the reporting period[7] - The company's total equity as of March 31, 2023, was CNY 7,126,636,403.82, compared to CNY 7,065,048,650.87 at the beginning of the year, reflecting a growth of about 0.9%[13] Research and Development - Research and development expenses surged by 398.74% to ¥691,393.55, indicating increased investment in R&D projects[5] - Research and development expenses for Q1 2023 were CNY 691,393.55, significantly higher than CNY 138,626.92 in Q1 2022, marking an increase of approximately 397.5%[16] Other Income - The company reported a significant increase in other operating income, which rose by 447.32% to ¥1,217,905.71 compared to ¥222,522.05 in the previous year[5] Equity and Returns - The weighted average return on equity decreased by 0.33 percentage points to 0.77% from 1.10% year-on-year[2]